Real-World Treatment Persistence with Vedolizumab in Crohn's Disease and Ulcerative Colitis Patients in the United States (US): A Retrospective Analysis Using the Optum Research Database

被引：2
|
作者：
Demuth, Dirk [1 ]
Patel, Haridarshan [2 ]
Chastek, Benjamin [3 ]
Lee, Brekke [3 ]
Khalid, Javaria Mona [1 ]
Null, Kyle D. [4 ]
机构：
[1] Takeda Dev Ctr Europe Ltd, London, England
[2] Immens Consulting Inc, Chicago, IL USA
[3] Optum Life Sci Inc, Eden Prairie, MN USA
[4] Takeda Pharmaceut USA Inc, Meridian, MS USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2016年 / 111卷
关键词：
D O I：
10.14309/00000434-201610001-00721
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
721
引用
收藏
页码：S324 / S324
页数：1
相关论文
共 50 条
  • [1] Real-World Treatment Persistence with Vedolizumab in Patients with Ulcerative Colitis and Crohn's Disease: A Retrospective Claims Analysis in the US
    Null, Kyle D.
    Visaria, Jay
    Demuth, Dirk
    Patel, Haridarshan
    Zhou, Siting
    Lissoos, Trevor
    Luo, Michelle
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 : S322 - S324
  • [2] Real-world treatment persistence with vedolizumab in Crohn's disease and ulcerative colitis patients
    Raluy, M.
    Fraeman, K.
    Donaldson, R.
    Reynolds, M.
    Smyth, M.
    Demuth, D.
    Khalid, J. M.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S173 - S174
  • [3] vedolizumab versus infliximab and adalimumab in the real-world persistence in Ulcerative Colitis and Crohn's disease - a meta-analysis
    Yiu, T. H.
    Leong, R.
    Ko, Y.
    Pudipeddi, A.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 694 - 694
  • [4] Clinical characteristics of patients with Crohn's disease or ulcerative colitis treated with vedolizumab: a real-world data analysis
    Liang, H.
    Manne, S.
    Shick, J.
    Yu, S.
    Fusco, G.
    Dolin, P.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S466 - S467
  • [5] Clinical Characteristics of Patients With Crohn's Disease or Ulcerative Colitis Treated With Vedolizumab - A Real-World Data Analysis
    Liang, Huifang
    Manne, Sudhakar
    Shick, Jesse
    Yu, Shawn
    Fusco, Gregory
    Dolin, Paul
    GASTROENTEROLOGY, 2016, 150 (04) : S789 - S789
  • [6] VEDOLIZUMAB IN THE TREATMENT OF CROHN'S DISEASE AND ULCERATIVE COLITIS - NON-TERTIARY REAL WORLD ANALYSIS
    Ritchie, Susan
    Maw, Frances
    Hussien, Mohammed
    Fletcher, Victoria
    Crissop, Linda
    Jordan, Sarah
    Dhar, Anjan
    GUT, 2019, 68 : A92 - A92
  • [7] Good efficacy and safety of vedolizumab in Crohn's disease and ulcerative colitis in a real-world scenario
    Zingone, Fabiana
    Barberio, Brigida
    Compostella, Federico
    Girardin, Giulia
    D'Inca, Renata
    Marinelli, Carla
    Marsilio, Ilaria
    Lorenzon, Greta
    Savarino, Edoardo Vincenzo
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2020, 13
  • [8] Hospitalizations and Characteristics of Patients with Ulcerative Colitis and Crohn's Disease Treated with Vedolizumab in the United States
    Reynolds, Matthew
    Raluy-Callado, Mireia
    O'Hara, Don
    Alam, Naufil
    Smyth, Michael
    Khalid, Mona
    INFLAMMATORY BOWEL DISEASES, 2016, 22 : S17 - S17
  • [9] Real-World Outcomes of Vedolizumab Therapy in Ulcerative Colitis and Crohn's Disease at a Tertiary Referral Center
    Hoffmann, Peter
    Krisam, Johannes
    Stremmel, Wolfgang
    Gauss, Annika
    DIGESTIVE DISEASES, 2019, 37 (01) : 33 - 44
  • [10] A real-world study of outcomes in biologic-naive patients with Crohn's disease and ulcerative colitis initiating vedolizumab
    Raluy, M.
    Alam, N.
    Donaldson, R.
    Smyth, M.
    Khalid, J. M.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S238 - S238
12345